Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADZENYS ER vs ADDERALL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ADZENYS ER is a central nervous system (CNS) stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
Adderall 15 is a combination of amphetamine and dextroamphetamine, which increase synaptic concentrations of norepinephrine and dopamine by inhibiting their reuptake and promoting their release from presynaptic terminals.
Attention Deficit Hyperactivity Disorder (ADHD)
Attention deficit hyperactivity disorder (ADHD),Narcolepsy
Adults: Initial 5-10 mg orally once daily; titrate in 5-10 mg increments weekly to optimal response; max 60 mg/day.
10-20 mg orally once daily in the morning; may increase by 5-10 mg weekly; maximum 40 mg/day.
6-8 hours in adults; in children 3-6 hours, requiring twice-daily dosing for sustained effect
Mean terminal half-life: d-amphetamine 10 h, l-amphetamine 13 h (range 9-14 h); for ADDERALL 15 (3:1 mix), effective half-life ~11 h; clinical context: dosing interval typically QD-BID.
Metabolized primarily by hepatic esterases and cytochrome P450 (CYP) enzymes, including CYP2D6.
Amphetamine is metabolized primarily by hepatic CYP2D6 and to a lesser extent by CYP2C19 and CYP2C9, with some minor pathways involving dopamine beta-hydroxylase.
70% renal (30% unchanged, 40% as metabolites), 30% fecal/biliary
Primarily renal (90% as unchanged drug and metabolites; ~30% unchanged, 40% as 4-hydroxyamphetamine and conjugates, 20% as other metabolites); minimal biliary/fecal elimination (<3%).
97% bound to albumin and α1-acid glycoprotein
~16-20%; primarily binds to albumin, with minor binding to alpha-1-acid glycoprotein.
4.6-6.8 L/kg, indicating extensive tissue distribution, particularly in brain and adipose tissue
Vd: 3.0-4.5 L/kg (range 2.6-5.6); indicates extensive tissue distribution, including brain, with accumulation in kidneys and liver.
Oral: 95% ± 10%; rectal: 80% ± 15%
Oral: ~76% (range 64-95%) for mixed amphetamine salts; bioavailability reduced by acidic gastric p H and increased with food (Tmax delayed but AUC unchanged).
GFR 30-89 m L/min: No adjustment. GFR <30 m L/min: Not recommended.
GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: contraindicated.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Children ≥6 years: Initial 5-10 mg orally once daily; titrate weekly by 5-10 mg; max 1 mg/kg/day or 60 mg/day, whichever is lower.
Weight-based: <50 kg: 2.5-5 mg once daily; 50-100 kg: 5-10 mg once daily; >100 kg: adult dosing.
Initiate at 5 mg once daily; titrate cautiously; monitor for cardiovascular effects and insomnia.
Start at 2.5-5 mg once daily; increase slowly due to increased sensitivity and cardiovascular risk.
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including ADZENYS ER, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including Adderall, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence throughout therapy.
Serious cardiovascular events: Sudden death, stroke, and myocardial infarction have been reported in patients with pre-existing cardiac abnormalities.,Blood pressure and heart rate increase: Monitor regularly.,Psychiatric adverse reactions: May precipitate or exacerbate psychosis or mania.,Long-term suppression of growth in pediatric patients: Monitor height and weight.,Seizures: May lower seizure threshold in patients with history of seizures.,Peripheral vasculopathy: Including Raynaud's phenomenon.
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems,Blood pressure and heart rate increases,Psychiatric adverse events (exacerbation of pre-existing psychosis, manic episodes, aggressive behavior),Seizures (may lower seizure threshold),Peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome risk, especially with concomitant serotonergic drugs,Long-term growth suppression in children
Known hypersensitivity to amphetamines or other components of ADZENYS ER,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI,Agitated states,History of drug abuse,Cardiovascular disease including hypertension, arteriosclerosis, hyperthyroidism, glaucoma
Hypersensitivity to amphetamine or other components,Concurrent use or within 14 days of MAOIs (risk of hypertensive crisis),Glaucoma,Hyperthyroidism,Agitated states,History of drug abuse,Cardiovascular disease (symptomatic, moderate to severe hypertension, advanced arteriosclerosis, structural cardiac abnormalities)
High-fat meals can significantly delay and reduce the absorption of Adzenys ER; the time to peak concentration (Tmax) may be prolonged by approximately 1 hour and peak concentration (Cmax) reduced by about 38%. It is recommended to take Adzenys ER on an empty stomach (at least 1 hour before or 2 hours after a meal) to ensure consistent effect. Avoid alcohol while taking this medication, as it may increase the risk of cardiovascular side effects and impair judgment. No other specific food interactions are known, but patients should maintain a balanced diet to manage potential appetite suppression common with amphetamines.
Avoid high-fat meals close to dosing as they may delay absorption. Acidic foods (e.g., citrus, cola, vitamin C) can decrease absorption; take with non-acidic fluids. Avoid alcohol and caffeine-containing products.
First trimester: Inadequate human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: Chronic use may lead to neonatal withdrawal syndrome (hyperactivity, irritability, poor feeding) and reduced fetal growth. Avoid in first trimester unless benefit outweighs risk; use lowest effective dose in later trimesters.
First trimester: Possible increased risk of congenital malformations (cardiac, oral clefts) based on limited human data; animal studies show dose-dependent teratogenicity. Second/third trimesters: Risk of fetal growth restriction, preterm delivery, neonatal withdrawal (irritability, feeding problems), and persistent pulmonary hypertension.
Excreted in breast milk; M/P ratio approximately 2.6. Irritability and weight loss reported in nursing infants. Not recommended unless benefit outweighs risk.
Present in breast milk; M/P ratio approximately 2.5-7.5. Potential for infant stimulation, insomnia, reduced weight gain. Caution recommended; consider delaying breastfeeding until 1-2 hours after dose.
Clearance increased by approximately 30% in third trimester; may require dose escalation. Postpartum dose reduction may be needed to avoid toxicity. Individual titration based on clinical response and tolerability.
Pregnancy reduces amphetamine plasma concentrations by 15-50% during second/third trimesters due to increased clearance. Dose may need upward titration to maintain clinical effect, with careful monitoring for adverse effects.
Adzenys ER is an extended-release oral suspension of amphetamine (mixed salts) for ADHD. It provides a rapid onset (within 1 hour) and sustained effect over 10-12 hours. The suspension must be shaken vigorously for at least 10 seconds before each use. Dose titration should be guided by efficacy and tolerability, starting at 6.3 mg once daily in the morning for children 6-12 years. Avoid administration with high-fat meals as they may delay absorption (Cmax reduced by ~38%). Monitor for cardiovascular effects: heart rate, blood pressure, and potential for sudden death in patients with structural cardiac abnormalities. Use cautiously in patients with pyschosis, bipolar disorder, hypertension, hyperthyroidism, glaucoma, or history of drug abuse. Discontinue if agitation, aggression, or manic symptoms emerge. Drug holidays (weekend or holiday breaks) may be considered to assess need and reduce tolerance.
Adderall 15 mg (amphetamine/dextroamphetamine) is an immediate-release formulation; onset 30-60 min, duration 4-6 hours. Avoid afternoon doses to prevent insomnia. Monitor for hypertension, tachycardia, and growth suppression in children. Consider drug holidays to assess need and reduce tolerance. Do not use with MAOIs or within 14 days of MAOI therapy. Risk of abuse and dependence; screen for substance use history. Use with caution in patients with pre-existing cardiovascular disease or psychiatric disorders.
Take Adzenys ER exactly as prescribed, once daily in the morning; do not take in the afternoon or evening to avoid insomnia.,Shake the bottle vigorously for at least 10 seconds before each use; use the provided oral syringe to measure the correct dose.,Do not mix the medication with food or liquids; take it directly from the syringe.,Avoid taking with high-fat meals, as they may delay and reduce the drug's effect; take on an empty stomach if possible.,Store at room temperature (20-25°C); protect from light and moisture. Discard any unused portion after 30 days of opening.,Notify your doctor immediately if you experience chest pain, shortness of breath, fainting, or palpitations.,This medication has a high potential for abuse; do not share it with others and keep in a safe place.,Inform your doctor about all other medications, including OTC drugs and supplements, especially MAOIs (avoid within 14 days), antihypertensives, and SSRIs.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Take the first dose in the morning; if prescribed a second dose, take it by early afternoon to avoid sleep problems.,Swallow tablet whole; do not crush or chew.,Avoid alcohol and caffeine; may increase side effects like nervousness and rapid heartbeat.,Report chest pain, palpitations, shortness of breath, or fainting immediately.,Inform your doctor of all medications, including over-the-counter and herbal products, especially antidepressants.,May cause weight loss; monitor growth in children.,Can impair ability to drive or operate machinery until you know how it affects you.,Store at room temperature away from moisture and heat.,Do not abruptly stop; taper under medical supervision to avoid withdrawal.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADZENYS ER vs ADDERALL 15, answered by our medical review team.
ADZENYS ER is a CNS Stimulant that works by ADZENYS ER is a central nervous system (CNS) stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.. ADDERALL 15 is a CNS Stimulant that works by Adderall 15 is a combination of amphetamine and dextroamphetamine, which increase synaptic concentrations of norepinephrine and dopamine by inhibiting their reuptake and promoting their release from presynaptic terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADZENYS ER and ADDERALL 15 depend on the specific clinical indication. These are both CNS Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADZENYS ER is: Adults: Initial 5-10 mg orally once daily; titrate in 5-10 mg increments weekly to optimal response; max 60 mg/day.. The standard adult dose of ADDERALL 15 is: 10-20 mg orally once daily in the morning; may increase by 5-10 mg weekly; maximum 40 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADZENYS ER and ADDERALL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADZENYS ER is classified as Category C. First trimester: Inadequate human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: Chronic use may lead to neonata. ADDERALL 15 is classified as Category C. First trimester: Possible increased risk of congenital malformations (cardiac, oral clefts) based on limited human data; animal studies show dose-dependent teratogenicity. Second/t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.